Benjamin Levy, MD, discusses how the role of immunotherapy has evolved in the treatment landscape of lung cancer and where he sees this research headed in the future.
6206507505001Benjamin Levy, MD, clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses how the role of immunotherapy has evolved in the treatment landscape of lung cancer and where he sees this research headed in the future.
There are now 9 approvals for different immunotherapy agents for the treatment of patients with advanced lung cancer without a mutation, Levy says. It’s important to know that there are even patients experience long-term survival benefits with immunotherapy, much like targeted agents that have become available and are showing promise in this space.
Levy reflects on previous phase 1 data, in which the 5-year overall survival rate with nivolumab was 16%. The patients here received an average line of 3 prior therapies, and this demonstrates some of the early efficacy observed for this therapeutic approach.
The question is how to move this into earlier stages of disease. Immunotherapy is also appearing promising in the neoadjuvant setting, where patients receive the treatment prior to surgery, Levy says.
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More